Undisclosed HuCal antibody for ophthalmology: Phase I started

Novartis began a Phase I trial of an undisclosed HuCAL antibody. The start triggers an undisclosed milestone payment to MorphoSys, which is using its HuCAL GOLD technology to discover and optimize ant...